Clinical Trials Sponsored by Jiangsu Rec-Biotechnology Co., Ltd.

Total 1528 results

Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia

Immune Thrombocytopenia

China
Jiangsu Simcere Pharmaceutical Co., Ltd.

Recruiting

An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.

Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer

Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

An Investigational Study of SHR3680 in Participants With Mild to Moderate Liver Impairment and Healthy Participants

Hepatic Impairment | Healthy Participants

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

Relapsed Ovarian Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer

Pancreatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Renal Cell Carcinoma | Cervical Cancer | Endometrial Cancer | Urothelial Carcinoma | Ovarian Cancer Recurrent

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR-1701 in Metastatic or Locally Advanced Solid Tumors

Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active, not recruiting

KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

Advanced Pancreatic Ductal Adenocarcinoma

China
Jiangsu Simcere Pharmaceutical Co., Ltd.

Completed

Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects

Healthy Volunteer

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer

Gastric/Gastroesophageal Junction Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma

Sarcoma

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Assessment of Gastric Emptying by SHR20004 in Healthy Subjects

Type 2 Diabetes Mellitus

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

The Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Healthy Subject

Diabetes

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Locally Advanced or Metastatic and Unresectable HCC

United States, Spain, China, Taiwan, Belgium, Korea, Republic of, Italy, Hong Kong, Russian Federation, Ukraine, Turkey, Poland, Germany
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

Esophageal Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

Gastric Cancer | GastroEsophageal Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Hetrombopag or Placebo in Treatment-Naive Severe Aplastic Anemia

Severe Aplastic Anemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability

Graft-versus-host Disease

China
Jiangsu Simcere Pharmaceutical Co., Ltd.

Completed

The Tolerability, Safety, and PK Characteristics of SIM1910-09 in Healthy Chinese Volunteers

Acute Ischemic Stroke | Cerebral Edema

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype

Asthma With Eosinophilic Phenotype

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors

Advanced Malignancies

Australia, China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer

Hormone Sensitive Prostate Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study of Irinotecan Liposome in Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer

Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis

Moderate-to-severe Chronic Plaque Psoriasis

United States, Australia, China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

A Study of HS-10353 in Chinese Participants.

Major Depressive Disorder

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

To Compare the Pharmacokinetics and Pharmacodynamics of HR20014, INS068 and INS062 After Single Subcutaneous Injection in Healthy Subjects

Diabetes

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer

HER2-positive Metastatic Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Omeprazole on the Pharmacokinetics of SHR6390 in Healthy Subjects

Advanced Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors

Advanced Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Drug-drug Interaction Study of Famitinib Malate With a Proton Pump Inhibitor in Healthy Adult Subjects

Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage

Primary Hypercholesterolemia | Mixed Hyperlipemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition

Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Breast Cancer | Triple Negative Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Efficacy and Safety of SHR8028 Eye Drops for the Treatment of Dry Eye Disease

Dry Eye Disease

China
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Terminated

KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent

Advanced Non-small Cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR - 1209 Treatment Efficacy and Safety of the Patients With Hypercholesterolemia Ⅲ Period Clinical Research

Primary Hypercholesterolemia

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Hepatocellular Carcinoma (HCC)

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Active, not recruiting

Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection

Chronic HBV Infection

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

A Study of HS-10342 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

Study of the Efficacy and Safety of Pegol-Sihematide for Anemia in Patients With Chronic Kidney Disease on Dialysis

Chronic Kidney Diseases

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

A Study To Evaluate The Safety, Tolerability And Pharmacokinetics of HS-10345 In Treatment-Resistant Depression

Treatment Resistant Depressive Disorder

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma

Advanced Melanoma

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Advanced Biliary Tract Carcinoma | Advanced Primary Liver Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy (PASSION)

Small-cell Lung Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects

HER2-positive Recurrent / Metastatic Breast Cancer

China
Alpha Biopharma (Jiangsu) Co., Ltd.

Completed

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases (BM)

Non-small Cell Lung Cancer | Brain Metastases | EGFR Gene Mutation

China, Korea, Republic of, Singapore, Taiwan
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor

Mature B Cell Neoplasms

China

3

Subscribe